US FDA approves first mRNA flu shot from Moderna
The U.S. FDA approved Moderna’s mRNA flu vaccine mFlusiva for adults 50 and older, with traditional approval for ages 50-64 and accelerated approval for 65+. Based on a late-stage trial of 40,000+ adults, it was 26.6% more effective than a standard-dose flu vaccine. Moderna expects no meaningful revenue until H2 2027.
How this was made
The 30-second read
Why it matters
mFlusiva’s approval is a de-risking event for Moderna’s seasonal flu strategy, but the commercial ramp is constrained by missing the 2026 US contracting cycle and by the need for additional 65+ confirmation data.
Market read
Traders can treat this as a fresh regulatory catalyst for MRNA, with near-term fundamentals likely limited by the stated revenue timing.
What to watch
The article notes Moderna withdrew a COVID-flu combo shot application and faced FDA scrutiny under prior leadership, so future regulatory posture could still affect the broader pipeline timeline.
Background
The FDA approval is described as the first seasonal flu authorization for an mRNA-based vaccine, with traditional approval for ages 50-64 and accelerated approval for 65+ pending additional study.
Ticker impact
The FDA approved Moderna’s mRNA seasonal flu shot mFlusiva for adults 50+, including accelerated approval for ages 65+, creating a new regulatory milestone.
Likely positive medium-term bias for MRNA on approval optics, partially offset by the article’s note that meaningful revenue is not expected until 2H 2027.
The article provides a concrete FDA approval event plus trial efficacy and an explicit revenue timing caveat, which together define both upside (approval) and limitation (commercial ramp delay).
Market effects
Strengthens the mRNA vaccine platform narrative in seasonal influenza and may increase competitive pressure on conventional and high-dose flu vaccine makers.
Primarily US regulatory and commercial implications for the seasonal flu market.
Could support future international uptake of mRNA flu approaches, though the article focuses on US approval and US contracting cycles.
Counterpoint
The approval may be largely priced in for mRNA investors, and the delayed revenue window (2H 2027) limits immediate earnings impact.
Key entities
- companyModerna
Receives FDA approval for mFlusiva, an mRNA seasonal flu vaccine, with efficacy and antibody-response data cited.
- regulatorU.S. Food and Drug Administration
Granted traditional and accelerated approvals for mFlusiva in specified adult age groups.
- companySanofi
Its high-dose flu vaccine is referenced as a comparator for antibody responses in adults 65+.
